Related Experiment Video
Updated: Dec 10, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Progress of research on dyslipidemia accompanied by nephrotic syndrome
Min Tao1, Hai-Ping Wang1, Jing Sun1
1Department of Nephrology, Shandong Provincial Hospital, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong 250021, China.
Insights
Dyslipidemia, a common complication of nephrotic syndrome, increases the risk of cardiovascular and renal diseases. Understanding its mechanisms is crucial for developing effective treatments beyond current statin therapy.
Area of Science:
- Nephrology
- Cardiology
- Metabolic Diseases
Background:
- Nephrotic syndrome frequently presents with dyslipidemia, a significant risk factor for cardiovascular and renal complications.
- Dyslipidemia in this context can lead to atherosclerosis, glomerulosclerosis, tubulointerstitial injury, and thromboembolism.
- Long-term uncontrolled dyslipidemia is associated with a poor prognosis and contributes to disease progression.
Purpose of the Study:
- To investigate the underlying mechanisms of dyslipidemia in nephrotic syndrome.
- To provide detailed perspectives and analyses to aid in the development of improved treatment guidelines.
- To explore potential therapeutic targets beyond current interventions.
Main Methods:
- Analysis of lipoprotein metabolism, including hepatic synthesis and clearance.
- Investigation of the role of hepatic and lipoprotein lipase activities.
- Clinical characterization of hypertriglyceridemia and hypercholesterolemia in affected patients.
Main Results:
- Dyslipidemia is characterized by increased hepatic lipoprotein synthesis and decreased clearance.
- Downregulation of hepatic and lipoprotein lipase activities contributes to altered lipid profiles.
- Clinical manifestations include hypertriglyceridemia and hypercholesterolemia.
Conclusions:
- Dyslipidemia is a complex condition in nephrotic syndrome with multifactorial causes.
- Further research into dyslipidemia mechanisms is essential for refining treatment strategies.
- Current treatments like statins target hepatic cholesterol production and LDL-C absorption, but other therapies may be needed.
Abstract:
Nephrotic syndrome is a relatively common clinical disease. Associated dyslipidemia is a risk factor for the occurrence and development of cardiovascular and renal diseases that might gradually develop into atherosclerosis, glomerulosclerosis or tubulointerstitial injury. It also confers an elevated risk of complications such as thromboembolism. If not properly controlled over the long term, dyslipidemia will become a key factor in a poor prognosis. Furthermore, dyslipidemia correlates with an increase in hepatic compensatory synthetic lipoprotein levels and a decrease in lipoprotein clearance, which can be sourced to the downregulation of hepatic and lipoprotein lipase activities in endothelial cells, muscle, and adipose tissue, and clinically characterized as hypertriglyceridemia or hypercholesterolemia. However, further investigations into the mechanism(s) of dyslipidemia are needed, with the resultant detailed perspectives and analyses substantially aiding the further development of treatment guidelines. Currently, statins represent the most popular type of pharmaceutical intervention because they lower hepatic cholesterol production and promote the absorption of low-density lipoprotein-cholesterol from the bloodstream, followed by second-line and other potential therapies to regulate the expression of specific receptors.
Related Concept Videos
01:24Nephrotic Syndrome I : Introduction
01:24Nephrotic Syndrome III : Nursing Management
01:26Nephrotic Syndrome II : Assessment and Medical Management
01:24Chronic Kidney Disease II: Clinical Manifestations
01:26Atherosclerosis III: Management
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents